Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Urologix CEO Stryker Warren To Retire

Urologix, Inc. (ULGX: Quote) said Tuesday that Stryker Warren jr. has decided to retire as CEO and a member of the company's Board of Directors, effective November 30.

The company said its Chief Operating Officer Greg Fluet will become interim CEO following Warren's retirement.

Fluet joined the company as its Executive Vice President and Chief Operating Officer in July 2008. Prior to joining Urologix, he was an Associate at Sapient Capital Management, LLC, a venture capital firm focused on medical devices.

Warren came out of retirement to join Urologix as CEO in June 2008. He had previously been the President and CEO of Urology Healthcare Group whose wholly owned subsidiary, Urotech, remains Urologix' largest customer.

Click here to receive FREE breaking news email alerts for UROLOGIX INC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Less than a month after resigning from Congress, former House Majority Leader Eric Cantor, R-Virg., has made the move from Washington to Wall Street by joining boutique investment bank Moelis & Co. A statement from Moelis said Cantor will serve as Vice Chairman and Managing Director and also be elected to the company's Board of Directors. Stocks continue to show a lack of direction in mid-day trading on Tuesday following the long, holiday weekend. Even with the lackluster performance, the markets are largely holding on to the bulk of their recent gains. After reporting an unexpected drop in U.S. construction spending in the previous month, the Commerce Department released a report on Tuesday showing that construction spending rebounded by more than expected in the month of July.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.